Articles From: Operations Resume at Buenaventura’s Uchucchacua Mine to Opexa Therapeutics’ CEO Featured in Leading Life Science Publication


Compañia de Minas Buenaventura S.A.A. (“the Company” or “Buenaventura”) (NYSE: BVN; Lima Stock Exchange: BUE.LM) announced today that beginning Saturday, December 7 the Uchucchacua’s workers’ and contractors’ unions voluntarily concluded the strike that began December 4.
Sign-up for Operations Resume at Buenaventura’s Uchucchacua Mine investment picks
2014/3/17
Compañia de Minas Buenaventura S.A.A. (“the Company” or “Buenaventura”) (NYSE: BVN; Lima Stock Exchange: BUE.LM) announced today that beginning Sunday, March 16 at 07.00 am, the Uchucchacua’s contractors’ unions voluntarily concluded the stoppage that began March 11, 2014.
Sign-up for Operations Resume at Buenaventura’s Uchucchacua Mine investment picks
2013/10/3
By Hiroyuki Kachi Japanese retail giant Seven & i Holdings Co.
Sign-up for Operator of 7-Eleven chain reports strong growth investment picks
2014/3/18
BERWICK, Pa.
Sign-up for Operators Reconnect Unit 2 at PPL Susquehanna After Completing Planned Turbine Inspection investment picks
2014/3/26
BERWICK, Pa.
Sign-up for Operators Reconnect Unit 2 at Susquehanna Nuclear Power Plant investment picks
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biotechnology company developing Tcelna ® , a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the conversion of the Company’s outstanding 12% convertible secured promissory notes into shares of common stock.
Sign-up for Opexa Announces Conversion of all Convertible Secured Promissory Notes into Common Stock investment picks
2013/8/27
Opexa Therapeutics, Inc. (NASDAQ: OPXA) , a biotechnology company developing Tcelna ® , a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that several key patents have issued, further strengthening the Company's proprietary technology for the development of patient-specific immunotherapies.
Sign-up for Opexa Announces Issuance of 50th Patent for T-cell Immunotherapy Platform investment picks
2013/9/30
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ® , a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Neil K.
Sign-up for Opexa CEO Invited Panelist at 9th Annual Burrill Personalized Medicine Meeting investment picks
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ® , a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Neil K.
Sign-up for Opexa CEO Invited to Join Personalized Medicine Panel at New York CEO Conference investment picks
2013/8/13
Opexa Therapeutics, Inc. (NASDAQ: OPXA) , a biotechnology company developing Tcelna ® , a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that the company will report financial results for the three months ended June 30, 2013, before the opening of trading on Wednesday, August 14 th .
Sign-up for Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Second Quarter 2013 Financial Results investment picks
2013/11/6
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ® , a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that the company will report financial results for the three months ended September 30, 2013, before the opening of trading on Thursday, November 7 th .
Sign-up for Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Third Quarter 2013 Financial Results investment picks
2014/2/26
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ® , a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that the Company will report financial results for the year ended December 31, 2013, at the close of trading on Thursday, February 27, 2014.
Sign-up for Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Year End 2013 Financial Results investment picks
2014/3/20
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ® , a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the addition of two highly experienced individuals to join the Company’s Board of Directors.
Sign-up for Opexa Therapeutics Appoints Prof. Hans-Peter Hartung and Timothy Barabe to the Board of Directors investment picks
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biotechnology company developing Tcelna ® , a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Opexa will be highlighted in an upcoming broadcast of "The RedChip Money Report: Small Stocks Big Money," a nationally televised financial program.
Sign-up for Opexa Therapeutics CEO to Appear on The RedChip Money Report on Fox Business News investment picks
2014/2/11
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ® , a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Neil K.
Sign-up for Opexa Therapeutics CEO to Present at the 2014 Leerink Global Healthcare Conference investment picks
2014/1/23
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ® , a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Don Healey, Ph.D., Opexa’s Chief Scientific Officer, has been invited as a guest speaker to participate in the Phacilitate Cell & Gene Therapy Forum.
Sign-up for Opexa Therapeutics Chief Scientific Officer Invited as Guest Speaker at the Phacilitate Cell & Gene Therapy Forum investment picks
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ® , a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that the Company has been featured in Neurology Reviews .
Sign-up for Opexa Therapeutics Immune Monitoring Program Featured in Neurology Reviews investment picks
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ® , a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), is pleased to announce the enrollment of the 126 th patient in the Phase IIb “Abili-T” clinical study of Tcelna (imilecleucel-T) in patients with Secondary Progressive Multiple Sclerosis (SPMS). “We are pleased with the continued progress we have made in the Abili-T clinical trial and that patient enrollment has increased steadily over the past several months,” commented Neil K.
Sign-up for Opexa Therapeutics Provides MS Trial Enrollment Update; 70% of Patients Enrolled investment picks
Opexa Therapeutics, Inc. (NASDAQ: OPXA) , a biotechnology company developing Tcelna ® , a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended June 30, 2013 and provided an overview of recent corporate developments.
Sign-up for Opexa Therapeutics Reports Second Quarter 2013 Financial Results and Provides Corporate Update investment picks
2013/11/7
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ® , a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today reported financial results for the third quarter ended September 30, 2013 and provided an overview of the Company’s recent corporate developments.
Sign-up for Opexa Therapeutics Reports Third Quarter 2013 Financial Results and Provides Corporate Update investment picks
2014/2/27
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing a novel T-cell immunotherapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2013, and provided an overview of recent corporate developments.
Sign-up for Opexa Therapeutics Reports Year End 2013 Financial Results and Provides Corporate Update investment picks
2013/11/12
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ® , a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced Opexa has been named one of the “Top Projects to Watch” in advanced therapeutics by Elsevier Business Intelligence.
Sign-up for Opexa Therapeutics Selected as a “Top 10 Advanced Therapy Projects to Watch” investment picks
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biotechnology company developing Tcelna ® , a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS) announced it will be a key sponsor of the National Multiple Sclerosis Society’s Walk MS series of events being held in the Houston area and Austin, Texas, during October and November.
Sign-up for Opexa Therapeutics Supports National Multiple Sclerosis Society as a Corporate Sponsor of Walk MS investment picks
2014/1/29
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ® , a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Neil K.
Sign-up for Opexa Therapeutics to Present at the 16th Annual BIO CEO & Investor Conference investment picks
Opexa Therapeutics, Inc. (NASDAQ: OPXA) , a biotechnology company developing Tcelna®, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the closing of the partial exercise of the over-allotment option granted to the underwriters to purchase an additional 650,000 shares of its common stock, at a price to the public of $1.50 per share, in connection with the Company’s recently announced underwritten public offering of 12,000,000 shares of common stock, bringing total gross proceeds from the offering to $18,975,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.
Sign-up for Opexa Therapeutics, Inc. Announces Closing of Partial Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock investment picks
2013/8/13
Opexa Therapeutics, Inc. (NASDAQ: OPXA) , a biotechnology company developing Tcelna®, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the closing of the previously announced underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $1.50 per share.
Sign-up for Opexa Therapeutics, Inc. Announces Closing of Public Offering of Common Stock investment picks
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna®, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the closing of the previously announced underwritten public offering of 4,120,000 shares of its common stock, including the full exercise of the over-allotment option granted to the underwriters to purchase an additional 618,000 shares of its common stock, at a price to the public of $1.70 per share.
Sign-up for Opexa Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares investment picks
Opexa Therapeutics, Inc. (NASDAQ:OPXA) , a biotechnology company developing Tcelna®, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the pricing of an underwritten public offering of 12 million shares of its common stock at a price to the public of $1.50 per share.
Sign-up for Opexa Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock investment picks
2013/12/17
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today announced that it intends to offer shares of its common stock in an underwritten secondary public offering.
Sign-up for Opexa Therapeutics, Inc. Announces Proposed Public Offering of Common Stock investment picks
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ® , a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Neil K.
Sign-up for Opexa Therapeutics’ CEO Featured in Leading Life Science Publication investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Operations Resume at Buenaventura’s Uchucchacua Mine to Opexa Therapeutics’ CEO Featured in Leading Life Science Publication
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity